Navigation auf uzh.ch
Navigation auf uzh.ch
1. Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors. de Andrade Pereira B, Fraefel C. Discov Med. 2015 Sep;20(109):111-9. Review.
2. Tolerance of activated pathogenic CD4+ T cells by transcriptional targeting of dendritic cells. de Andrade Pereira B, Ackermann M, Chaudhary S, Vogel R, Vogt B, Dresch C, Fraefel C. Gene Ther. 2015 May;22(5):382-90. doi: 10.1038/gt.2015.6.
3. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis. de Andrade Pereira B, Fraefel C, Hilbe M, Ackermann M, Dresch C. Gene Ther. 2013 May;20(5):556-66. doi: 10.1038/gt.2012.73.
4. Development of antigen cross-presentation capacity in dendritic cells. Dresch C, Leverrier Y, Marvel J, Shortman K. Trends Immunol. 2012 Aug;33(8):381-8. doi: 10.1016/j.it.2012.04.009. Review.
5. Thymic but not splenic CD8⁺ DCs can efficiently cross-prime T cells in the absence of licensing factors. Dresch C, Ackermann M, Vogt B, de Andrade Pereira B, Shortman K, Fraefel C. Eur J Immunol. 2011 Sep;41(9):2544-55. doi: 10.1002/eji.201041374.
